Oppenheimer Reaffirms Their Buy Rating on Zimmer Biomet Holdings (ZBH)

In a report released today, Steven Lichtman from Oppenheimer maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report), with a price target of $155.00. The company’s shares closed yesterday at $118.46.

According to TipRanks, Lichtman is a 5-star analyst with an average return of 12.1% and a 52.46% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, AngioDynamics, and Boston Scientific.

Currently, the analyst consensus on Zimmer Biomet Holdings is a Hold with an average price target of $135.53, which is a 14.41% upside from current levels. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $139.00 price target.

ZBH market cap is currently $24.52B and has a P/E ratio of 24.48.

Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zimmer Biomet Holdings (ZBH) Company Description:

Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company engages in designing, manufacturing and marketing orthopedic reconstructive products; biologics, sports medicine, extremities and trauma products; spine, dental implants, bone healing, craniomaxillofacial and thoracic products; and related surgical products.